Literature DB >> 1704414

Chemoprophylaxis of scrapie in mice.

H Diringer1, B Ehlers.   

Abstract

Three applications of the polyanion pentosanpolysulphate about 2 months before infection of mice with scrapie completely protected animals infected with up to 100 LD50, and considerably prolonged the lifespan of those infected with 100 to 10,000 LD50. The clinical diagnosis was confirmed by immunoblot analysis for the protein of scrapie-associated fibrils.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1704414     DOI： 10.1099/0022-1317-72-2-457

Source DB:  PubMed          Journal:  J Gen Virol        ISSN： 0022-1317            Impact factor:   3.891


  37 in total

1.  Neuroinvasion by a Creutzfeldt-Jakob disease agent in the absence of B cells and follicular dendritic cells.

Authors:  M J Shlomchik; K Radebold; N Duclos; L Manuelidis
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-24       Impact factor: 11.205

2.  Scrapie strains maintain biological phenotypes on propagation in a cell line in culture.

Authors:  C R Birkett; R M Hennion; D A Bembridge; M C Clarke; A Chree; M E Bruce; C J Bostock
Journal:  EMBO J       Date:  2001-07-02       Impact factor: 11.598

3.  Mefloquine, an antimalaria drug with antiprion activity in vitro, lacks activity in vivo.

Authors:  David A Kocisko; Byron Caughey
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

Review 4.  Transmissible spongiform encephalopathies (TSE) virus-induced amyloidoses of the central nervous system (CNS).

Authors:  H Diringer
Journal:  Eur J Epidemiol       Date:  1991-09       Impact factor: 8.082

5.  Opposite effects of dextran sulfate 500, the polyene antibiotic MS-8209, and Congo red on accumulation of the protease-resistant isoform of PrP in the spleens of mice inoculated intraperitoneally with the scrapie agent.

Authors:  V Beringue; K T Adjou; F Lamoury; T Maignien; J P Deslys; R Race; D Dormont
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

Review 6.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

7.  Specific glycosaminoglycan chain length and sulfation patterns are required for cell uptake of tau versus α-synuclein and β-amyloid aggregates.

Authors:  Barbara E Stopschinski; Brandon B Holmes; Gregory M Miller; Victor A Manon; Jaime Vaquer-Alicea; William L Prueitt; Linda C Hsieh-Wilson; Marc I Diamond
Journal:  J Biol Chem       Date:  2018-05-11       Impact factor: 5.157

8.  Fatal transmissible amyloid encephalopathy: a new type of prion disease associated with lack of prion protein membrane anchoring.

Authors:  Bruce Chesebro; Brent Race; Kimberly Meade-White; Rachel Lacasse; Richard Race; Mikael Klingeborn; James Striebel; David Dorward; Gillian McGovern; Martin Jeffrey
Journal:  PLoS Pathog       Date:  2010-03-05       Impact factor: 6.823

9.  Calcineurin inhibition at the clinical phase of prion disease reduces neurodegeneration, improves behavioral alterations and increases animal survival.

Authors:  Abhisek Mukherjee; Diego Morales-Scheihing; Dennisse Gonzalez-Romero; Kristi Green; Giulio Taglialatela; Claudio Soto
Journal:  PLoS Pathog       Date:  2010-10-07       Impact factor: 6.823

10.  Glypican-1 mediates both prion protein lipid raft association and disease isoform formation.

Authors:  David R Taylor; Isobel J Whitehouse; Nigel M Hooper
Journal:  PLoS Pathog       Date:  2009-11-20       Impact factor: 6.823
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.